Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.26) per share and revenue of $11.39 million for the quarter.

Intellia Therapeutics Stock Down 4.5 %

Shares of NTLA stock opened at $8.44 on Tuesday. The firm has a 50 day moving average of $8.30 and a 200-day moving average of $11.29. The company has a market cap of $874.24 million, a price-to-earnings ratio of -1.55 and a beta of 2.33. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.18.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wedbush reissued a “neutral” rating and set a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Oppenheimer reduced their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. HC Wainwright assumed coverage on Intellia Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $30.00 target price on the stock. Wolfe Research raised shares of Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 price target for the company in a research report on Monday, April 21st. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.68.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.